Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $84.14 USD
Change Today -0.37 / -0.44%
Volume 4.8M
LLY On Other Exchanges
New York
SIX Swiss Ex
EN Paris
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/13/15 - $90.18
52 Week Low
08/7/14 - $60.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Lilly Provides Update on Evacetrapib Phase 3 Trial

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility analysis. Last patient visit in ACCELERATE – which is evaluating evacetrapib in approximately 12,000 patients with high-risk atherosclerotic cardiovascular disease (ASCVD) – is expected in July 2016. Evacetrapib (LY2484595) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), and in clinical studies has demonstrated effects on high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and cholesterol efflux. Evacetrapib is in Phase 3 clinical studies and is not approved as a treatment for prevention or reduction of cardiovascular risk or any other indication anywhere in the world.

Eli Lilly Enters into Clinical Trial Collaboration with Immunocore

Eli Lilly and Company and Immunocore Limited have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore's T cell receptor-based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib and merestinib for the treatment of melanoma. The goal of the collaboration is to identify combination regimens that provide synergies in efficacy and durability in patients with metastatic cutaneous and uveal melanomas. Under the terms of the agreement, Immunocore and Lilly will conduct a Phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma. A second Phase Ib/II study will be conducted combining IMCgp100 with merestinib in metastatic uveal melanoma. Lilly will act as trial sponsor. These studies are anticipated to begin in 2016.

Biothera Announces Preclinical Research Collaboration with Eli Lilly and Company

Biothera announced that it has signed a collaborative research agreement with Eli Lilly and Company to evaluate in preclinical models the combination of Biothera's investigational immunotherapy Imprime PGG and Lilly's antiangiogenic therapy, ramucirumab (Cyramza). Emerging data illustrate the enormous potential of therapies that activate the immune system to recognize and eradicate cancer cells. In many cases, cancers reeducate the immune system to evade immune detection as well as to enable tumor cell survival. Therapies that can redirect the immune system and override the coopting signals elicited by the tumor are of particular interest. Lilly's ramucirumab may be one such therapy. By targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), ramucirumab blocks the neovascularization induced by tumors. Recent preclinical evidence suggests that by blocking tumorinduced blood vessel formation, and normalizing the vasculature, antiangiogenics like ramucirumab may help to "normalize' the immune infiltrate, creating an immune microenvironment capable of recognizing and attacking the cancer. Biothera presented data showing that Imprime PGG can initiate a cascade of immune responses through activation of both the innate and adaptive immune systems that also reorients the immune microenvironment, facilitating tumor recognition and destruction by immune cells.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $84.14 USD -0.37

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.50 USD -0.19
AbbVie Inc $69.73 USD -0.28
Bristol-Myers Squibb Co $65.34 USD -0.30
Medtronic PLC $78.00 USD -0.39
Teva Pharmaceutical Industries Ltd $70.06 USD +1.04
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 43.9x
Price/Sales 4.6x
Price/Book 6.1x
Price/Cash Flow 45.5x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at